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Background: MYCN oncogene amplification is the most important prognostic factor in neuroblastoma. 25%
neuroblastoma tumors have somatic amplifications at this locus but little is known about its constitutional
aberrations and their potential role in carcinogenesis. Here, we have performed an array-CGH and qPCR
characterization of two patients with constitutional partial 2p trisomy including MYCN genomic region.
Results: One of the patients had congenital neuroblastoma and showed presence of minute areas of gains and
losses within the common fragile site FRA2C at 2p24 encompassing MYCN. The link between 2p24 germline
rearrangements and neuroblastoma development was reassessed by reviewing similar cases in the literature.
Conclusions: It appears that constitutional rearrangements involving chromosome 2p24 may play role in NB
development.
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Congenital chromosomal aberrations have been of help
in identification of causative tumor suppressor gene (TSG)
in oncology, to name just two most notorious: WT1 at
11p13.1 and RB1 at 13q14.1. Since constitutional deletions
and translocations are often the first indicators of the
presence of TSGs, the pursue for patients with neuroblast-
oma (NB) and a concomitant constitutional genomic dis-
order has started. Disappointingly, so far only a dozen of
cases with a germinal chromosomal aberration have been
reported to develop NB (Additional file 1: Table S1). Of
these, only two regions were found to be affected repeat-
edly: a loss at chromosome 1p36 and a gain of chromo-
some 2p. Chromosome 1p36 is known to be deleted in ca.
30% of primary NB tumors, being one of the most com-
mon somatic cytogenetic abnormalities of recognizable
prognostic significance [1,2]. Accordingly, it has been pro-
posed as the putative locus for NB TSG, however so far no
major NB predisposition gene has been identified in this
region [3].* Correspondence: b.lipska@gumed.edu.pl
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reproduction in any medium, provided the orConversely, with respect to chromosome 2p two genes
involved in NB pathogenesis came into play. Germinal
activating mutation in ALK, an oncogene lying at chro-
mosome 2p23 has been recognized responsible for most
of the familial NB cases, while its somatic mutations are
present in 8% of sporadic tumors [4]. Then again, 2p24.3
is the locus of MYCN gene, amplification of which is
considered the most important factor of poor prognosis
in NB [5,6]. Since no clear correlation between constitu-
tional rearrangements involving chromosome 2p and the
role of ALK and/or MYCN in early stages of NB patho-
genesis has been established, in the current study we
have evaluated our two cases and reviewed all reported
NB with germinal cytogenetic rearrangements involving
chromosome 2p. We used array-CGH and qPCR tech-
niques for further delineation the minimal overlapping
region, identification of the causative genes and their
role in NB pathogenesis.
Results
Two patients with constitutional aberration including
partial 2p trisomy detected by classical cytogenetic stud-
ies were further evaluated using array-CGH. The patient
with NB was found to have 20.5 Mb duplication (arr
[hg18] 2p25.3p24.1(2,999-20,462,999)×3), while anothertd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(29,193-22,311,862)×3) at chromosome 2p together with
a deletion on chromosome 18q (arr[hg18] 18q22.3q23
(71,282,999-76,112,910)×1) and 17p (arr[hg18] 17p13.3
(29,169-2,867,570)×1) respectively. In both cases region
of gain encompassed MYCN genomic region but not
locus of ALK gene.
Evaluation of MYCN status in NB tumor was per-
formed by FISH, array-CGH and qPCR (Figure 1). Inter-
phase FISH showed MYCN gain nuc ish(MYCN×3-10)
[60] in the tumor cells, while evaluation of metaphase
chromosomes showed no signal translocation neither to
dmin nor to other chromosomes. Array-CGH showed
slight elevation of the log2 ratio between the blood and
the tumor and three independent qPCR experiments
targeting each of the MYCN exons further confirmed
MYCN gain. Besides, except for the unbalanced trans-
location, no other segmental chromosomal alterations or
regions with loss of heterozygosity (LOH) were detected
in the near-diploid tumor. ALK mutation status was
found not-mutated both at germinal and somatic level.
Precise delineation of the region of MYCN gain within
the area of duplication has been undertaken and a series
of qPCR targeting the adjacent genes have been de-
signed. As the reference, DNA from another patient with
constitutional aberration leading to partial 2p trisomy,Figure 1 Evaluation of MYCN status in the NB tumor of a patient with
MYCN status in the tumor “touch imprints” (red – MYCN, green – LAF at ch
extracted from the tumor hybridized against constitutional DNA of the sam
the log2 ratio, Y-axis: chromosomal coordinates according to NCBI36/hg18
(three independent qPCR amplicons) and the control gene ZNF2 (located anamely 46,XY,der(17)t(2;17)(p24.1;p13.3) was used. Fluc-
tuation of the gene copy number within the 15.5-19.5 Mb
region of the chromosome 2p, consistent with the bound-
aries of the common fragile site FRA2C has been observed
both at somatic, and to lower extent also at germinal level
in the NB patient. Conversely, the case without NB did
not present any fluctuation of the gene copy number in
the studied area (Figure 2).
Discussion
The database search for the patients with congenital
chromosomal aberrations who had NB retrieved seven
patients with aberrations involving chromosome 2p and
another seven cases with rearrangements of other chro-
mosomes (Additional file 1: Table S1). For the patients
sharing the 2p duplication, the minimal overlapping re-
gion was estimated to encompass 1.0 Mb at chromo-
some 2p24.1 (Figure 3). The region includes loci of
MYCN, DDX1 and partially FAM49A gene but not ALK
gene. The second chromosomal region involved in the
rearrangements was different in each of the 2p cases
reported so far. Hence it is most likely, the monosomy
of the chromosome 18q22.3-q23 does not have any rele-
vance to NB development in the child under study, espe-
cially that none of the genes mapping to this region is
considered to be a cancer-related gene.constitutional 2p duplication. A. Interphase FISH analysis of the
romosome 2q11.2). B. array-CGH analysis of the MYCN status. DNA
e patient (I) and against a pool of control reference DNA (II). X-axis:
. C. qPCR analysis of the MYCN status. The dosage of the MYCN gene
t chromosome 2q11.1).
Figure 2 Dosage of genes located within the MYCN amplicon. Tumor - somatic (NB tumor) DNA of the patient. Blood - constitutional
(peripheral blood leukocytes) DNA of the NB patient. Control - constitutional (peripheral blood leukocytes) of the control patient with
constitutional partial 2p duplication but no NB. X-axis chromosomal coordinates and gene locations are presented according to NCBI36/hg18;
Y-axis shows DNA ploidy. Genomic positions of the FRA2C fragile sites are given as established by Blumirch et al. [21].
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2p trisomy could be considered an overt causative agent
triggering NB development, since only a fraction (<10%)
of patients with constitutional 2p duplication eventually
develops NB [7-9]. To address the issue further, we have
compared two patients with constitutional rearrange-
ment at chromosome 2p involving MYCN but not ALK
locus, of whom only one developed NB. We have found
significant differences in gene copy number profile at
MYCN genomic region. Areas of gains and losses at
chromosome 2p24 were observed in the patient with
NB (Figure 2). On somatic level, similar aberration,including MYCN gain, was detected in the NB sample.
No other genetic event characteristic for NBs, including
other segmental chromosomal aberration(s), LOHs or
an ALK gene point mutation was found in the tumor.
Metaphase FISH studies showed uneven distribution
and variable degree of the gain in single cells reflecting
the heterogeneous character of the tumor. Since sec-
ondary numerical and segmental chromosomal alter-
ations are common findings in NB, this may explain
why in qPCR MYCN copy number was lower in tumor vs.
blood (Figure 2) given that the assay measures relative
dosage of the genes.
Figure 3 The range of chromosome 2p aberrations in patients with constitutional partial 2p trisomy and NB. Extend of the duplication
at 2p in each of the reported patients. Note that for two cases only (van Mater et al. and the current study) determination of the duplicated
region was performed on array-CGH level. Red-dashed area: minimal overlapping region of 1 Mbp (2:15,626,128-16,653,344), including the locus
of MYCN gene. Black asterisks: patients who had MYCN status evaluated in the tumor. Chromosomal coordinates presented according
to NCBI36/hg18.
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Even though large studies did not show its prognostic sig-
nificance [10] our data provide further evidence in favor
of its role at early stage of NB development and tumor
progression. In the light of the clinical variables: low-stage,
neonatal age at diagnosis, histopathology subtype and lack
of adverse genetic markers our patient should have been
classified as a low-risk NB. However, the uncertainty with
respect to the number of MYCN gene copies, eventually
classified as MYCN gain, and the natural history of other
NB patients with constitutional 2p duplication were the
two rationales for choosing an intensified strategy of treat-
ment to address the anticipated aggressive biology of the
tumor. All previously published patients with partial 2p
trisomy who were diagnosed with NB over the age of six
months had already progressed to metastatic disease at
the time of diagnosis [9,11-13]. Unfortunately, MYCN
amplification was assessed in three patients only (Figure 3).
The results were discordant: a case of a stage 1 NB was
found to have 3 copies of MYCN on array-CGH [14]; apatient with stage 4S NB was found to have MYCN gain
by FISH [15] and the third child with stage 4 NB was
found to have MYCN amplification presenting as multiple
double minutes (dmin) on FISH examination [9].
The molecular evaluation of the MYCN genomic region
allowed for detection of significant differences in gene copy
number pattern at the 2p24 locus suggestive for the pre-
sence of a cryptic complex genomic rearrangement (CGG)
in our NB patient. A number of models and processes have
been proposed to be involved in the origin of CGGs [16].
The ongoing debate seems to favor chromothripsis, the
one-off event to be responsible for most of the structural
aberrations in cancer [17]. Likewise, the recent analysis of
a series of patients with constitutional CGGs has shown
involvement of end-joining mechanism of double-stranded
DNA breaks resembling the chromothripsis-like chromo-
some catastrophes in their pathogenesis [18].
Moleenar et al. [19] were the first to report presence
of chromothripsis in 11% of primary NBs, on the whole
in older (>1.5 years) patients with MYCN amplified and
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tumors, chromothripsis resulted in amplification and
very strong overexpression of MYCN. Further evaluation
of high-risk NB by means of next-generation techniques
has shown no recurrent fusion transcripts and presence
of substantial local rearrangements in a minority of cases
only [3]. The later exclusively affected the vicinity ofMYCN
locus, with numerous complex copy number states and re-
tention of heterozygosity in lower-copy number regions.
Such a pattern of amplified/nonamplified regions within
the MYCN amplicon was already observed in a series of
NB cell lines [20]. The striking common denominator for
the aforesaid NB-related CGGs and the presented case is
the presence of minute areas of gains and losses in the
vicinity the MYCN gene. Blumirch et al. [21] have shown
that the boundaries of the CGGs involving MYCN de-
tected in NBs, and also observed in the present case, clus-
ter to the well known microhomology region: a common
fragile site FRA2C on chromosome 2p24 (Figure 2).
Common fragile sites (cFS) are evolutionarily conserved
AT-rich regions inherited within normal chromosomal
structure well known for their relative high mutation rate
[22]. When exposed to environmental factors that inter-
fere with DNA replication the accumulation of DNA sec-
ondary structures at cFS may give rise to double-strand
breaks, what in consequence may generate structural
chromosomal instability [23]. Our results suggest, that
the inherited unbalanced chromosomal aberration at 2p
may give grounds for nonrandom clustering of chromo-
somal breaks at the FRA2C leading to MYCN amplicon
formation.
Conclusions
To our knowledge, this is the first report of a case of a
constitutional genomic instability at MYCN locus detec-
ted in an neonate with an inherited unbalanced chromo-
somal rearrangement and neuroblastoma and no other
genomic alteration and/or known NB risk factor. It seems
that the germinal chromosomal aberration encompassing
MYCN locus without co-involvement of ALK gene was
sufficient to trigger cancerogenesis.
Methods
Patients
A patient with 46,XX,der(18)t(2;18)(p24;q23)mat present-
ing distinct dysmorphic features (dolichocephaly, midfa-
cial hypoplasia, large fontanella, hypotelorism, anteverted
nostrils, prominent philtrium, microretrognathia), con-
genital defects (ASD, PDA, cervical ribs, bilateral postaxial
polidactyly) and severe neonatal hypotonia was found to
have a suprarenal lesion on neonatal sonography. Further
image studies (MRI and metaiodobenzylguanidine (MIBG)
scintiscan) as well as bone-marrow biopsy showed pres-
ence of a single solid tumor lying in the left suprarenalarea, but with no sign of metastatic lesions or bone-
marrow involvement. At the age of 2 months surgery was
performed. In view of the final diagnosis of locoregional
Schwannian stroma-poor poorly differentiated NB (low
risk according to Shimada system and INRG consensus
pretreatment classification) the patient started chemother-
apy according to LINES 2009 (Low and Intermediate Risk
Neuroblastoma European Study) protocol, however after
two courses the parents declined from further oncological
treatment. Moreover, after defining maternal origin of the
translocation, the family refused further genetic evalu-
ation. The patient remains alive 2.5 years later with no
sign of disease recurrence.
The second patient with 46,XY,der(17)t(2;17)(p23;p13)
dn, is a mildly dysmorphic boy with multiple congenital
defects including lissencephaly, cryptorchidism, duplex
ureter (ureter fissus). The patient is subject to regular on-
cological surveillance by means of image studies and peri-
odical testing of urine catecholamine metabolite levels.
The child is alive with no sign of neoplastic process at the
age of 3.8 years.
DNA samples
DNA was isolated from the peripheral blood leukocytes
of two patients with constitutional partial 2p trisomy
and nine anonymous healthy female volunteers, which
were utilized as the reference control DNA. Constitutional
DNA samples used in array-CGH and qPCR experiments
were isolated using QIAamp DNA Blood Midi Kit (Qiagen).
Besides, tumor DNA, after verification of neoplastic cell
content to be exceeding 80%, was extracted from a fresh-
frozen neuroblastoma sample according to salting–out
protocol [24].
Karyotyping and fluorescent in situ hybridization
Cytogenetic studies were performed using conventional
GTG–banding of lymphocyte metaphase chromosomes
at a 550 band level following standard protocol. Double-
color fluorescent in situ hybridization (FISH) was per-
formed on interphase nuclei of NB tumor touch imprints
and on lymphocytes using Cytocell N-myc Amplification
Probe LPS009 for MYCN gene copy number detection. In
each analysis at least 60 nuclei were evaluated.
Targeted mutational analysis of ALK gene
Germline and somatic status of ALK at its mutational
hot-spot (exons 23–25) was evaluated through direct
sequencing (Applied Biosystem).
Array comparative genomic hybrydization
Array – CGH analysis of patients constitutional DNA
and tumor DNA was at first performed using high –
resolution Human CGH 2.1 M Whole-Genome Tiling
Array and later expanded using Human CGH 385 K
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37×1.4 M Arrays (NimbleGen, Roche) following the in-
structions provided by manufacturer. Arrays were scanned
with MS200 Microarray Scanner and analyzed using
NimbleScan, SignalMap and Deva v1.2.1 software
(NimbleGen, Roche). All identified genomic imbalances
were verified in the database of genomic variants (DGV;
http://dgv.tcag.ca; last accessed May 2013).Quantitative real – time PCR
The results of microarray study were validated by quantita-
tive real – time PCR (qPCR) performed on LightCycler480
System (Roche). Target genes: DDX1, MYCN, FAM49A,
SMC6, NT5C1B, OSR1 within the duplicated region (2p24)
were assessed against a control gene ZNF2 at 2q11.2 and
two reference genes GPR15 (3q11.2) and ERMP1 (9p24.1).
qPCR assays were performed using FastStart Universal
Probe Master and specific FAM pre – labelled probes
from Universal Probe Library (Roche). All samples were
run in triplicates. The dosage of target genes relative to
reference genes normalized to control DNA (same as
reference DNA used for array-CGH study) was assessed.Consent
Written informed consent was obtained from the legal
guardians of the patient (parents) for the publication of
the data presented in the report.Additional file
Additional file 1: Table S1. Patients with constitutional unbalanced
chromosomal aberrations who developed neuroblastoma. List of all patients
with constitutional chromosomal aberrations who developed neuroblastoma.
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